| 000 | 00853 a2200229 4500 | ||
|---|---|---|---|
| 005 | 20250513043902.0 | ||
| 264 | 0 | _c19950124 | |
| 008 | 199501s 0 0 eng d | ||
| 022 | _a0380-0903 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStrand, V | |
| 245 | 0 | 0 |
_aAre there special considerations relevant to trials of biologic agents? _h[electronic resource] |
| 260 |
_bThe Journal of rheumatology. Supplement _cSep 1994 |
||
| 300 |
_a41-5; discussion 45-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xtherapy |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 773 | 0 |
_tThe Journal of rheumatology. Supplement _gvol. 41 _gp. 41-5; discussion 45-9 |
|
| 999 |
_c7798741 _d7798741 |
||